LaunchPad: Exams/Dispensing Alcon Debuts iLux MGD Treatment System By Staff Tuesday, March 12, 2019 10:12 AM Product: iLux MGD Treatment SystemTop Line: Alcon unveiled the iLux MGD Treatment System at the SECO International 2019 annual meeting held recently in New Orleans. The device, which received approval from the Food and Drug Administration in December 2017, helps eyecare professionals provide comprehensive, in-office treatment for their patients with dry eye disease.Close Up: The innovative and personalized iLux MGD Treatment System addresses Meibomian Gland Dysfunction (MGD), a leading cause of dry eye. Handheld and portable, the iLux Device with Smart Tip Patient Interface enables ECPs to directly target a patient's blocked Meibomian glands through the application of light-based heat and compression under direct visualization. The device expands the company's current dry eye treatment offerings and allows practitioners to tailor treatment to the needs of each of their patients with dry eye disease in a matter of minutes.Vital Stats: The iLux device is indicated for the application of localized heat and pressure therapy in adult patients with chronic disease of the eyelids, including Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye. Do not use the iLux Device in patients with the following conditions: Patients whose pupils have been pharmaceutically dilated; patients who have undergone ocular surgery within prior 12 months; patients with ocular injury or trauma, chemical burns, or limbal stem cell deficiency (within prior three months); patients with active ocular herpes zoster or simplex of eye or eyelid or a history of these within prior three months; patients with cicatricial lid margin disease; patients with active ocular infection, active ocular inflammation or history of chronic, recurrent ocular inflammation within prior three months; patients with an ocular surface abnormality that may compromise corneal integrity; patients with lid surface abnormalities that affect lid function in either eye; patients with aphakia; or patients with permanent makeup or tattoos on their eyelids.www.alcon.com